FDA Fast Track Designation Granted for Investigational Osteoarthritis Treatment

Variance not fully explained by differences in access to healthcare providers or patient characteristics.
The FDA has granted Fast Track designation for GLPG1972/S201086 for the treatment of patients with osteoarthritis.

The US Food and Drug Administration (FDA) has granted Fast Track designation for GLPG1972/S201086 for the treatment of patients with osteoarthritis (OA).

The investigational molecule is a disease-modifying OA drug candidate that targets a cartilage-degrading enzyme called ADAMTS-5. Data from a phase 1 trial demonstrated that within 2 weeks, GLPG1972/S201086 reduced the blood level of ARGS neoepitope by approximately 50%. Similar findings were seen over a 4-week period in a Phase 1b trial including patients with OA from the United States. The treatment was well tolerated and reduced the ARGS neoepitope blood levels by up to 50%.

Related Articles

The ROCCELLA trial (ClinicalTrials.gov identifier: NCT03595618) will also evaluate the efficacy and safety of 3 different once-daily oral doses of GLPG1972/S201086. About 850 patients will be recruited from 15 countries. The primary end point of the ROCCELLA trial is to evaluate the efficacy of at least 1 dose of GLPG1972/S201086 compared with placebo in reducing cartilage loss after 52 weeks.

“The Fast Track designation by the FDA is a recognition of the high unmet medical need in OA, and the potential of GLPG1972/S201086 as a new treatment option,” stated Walid Abi-Saab, MD, CMO of Galapagos, in a press release. “Together with our collaboration partner Servier, we look forward to accelerating the development of GLPG1972/S201086 as a potential first disease-modifying osteoarthritis drug.”

Galapagos noteed that GLPG1972/S201086 is an investigational drug, and the efficacy and safety have not been established.


Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis [press release]. Mechelen, Belgium: Galapagos. http://www.glpg.com/press-releases. Published November 27, 2018. Accessed November 27, 2018.

This article originally appeared on Rheumatology Advisor